Literature DB >> 33150973

Kidney involvement in COVID-19 and its treatments.

Xiucui Han1, Qing Ye1.   

Abstract

The lungs are the most commonly affected organ by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the kidneys are also frequently affected. Infection with SARS-CoV-2 can not only cause new kidney damage but also increase the difficulty of treatment and care as well as mortality for people with underlying kidney diseases. Kidney involvement in SARS-CoV-2 infection mainly manifests as kidney tubular injury. Proteinuria is the main clinical sign. To reduce patient mortality, kidney complications should be given increased attention in the diagnosis and treatment of coronavirus disease 2019 (COVID-19). This study reviews the existing literature and discusses COVID-19 infection in combination with kidney diseases in terms of kidney damage, pathogenesis, and treatment to guide clinical anti-epidemic responses.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  coronavirus; cytokine/chemokine; endemic infection

Year:  2020        PMID: 33150973     DOI: 10.1002/jmv.26653

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  21 in total

Review 1.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

Review 2.  Spectrum of hematological changes in COVID-19.

Authors:  Smeeta Gajendra
Journal:  Am J Blood Res       Date:  2022-02-15

Review 3.  SARS-CoV-2 Spreads Globally Through the Object-to-Human Transmission of Cross-Border Logistics.

Authors:  Wenxia Shao; Qing Ye
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

Review 4.  Accurate Interpretation of SARS-CoV-2 Antigen Detection by Immunochromatography.

Authors:  Wenxia Shao
Journal:  Front Med (Lausanne)       Date:  2022-06-29

Review 5.  Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.

Authors:  Wenxia Shao; Weiying Zhang; Xiang Fang; Daojun Yu; Xianjun Wang
Journal:  J Microbiol Immunol Infect       Date:  2022-04-26       Impact factor: 10.273

Review 6.  Assessment of global asymptomatic SARS-CoV-2 infection and management practices from China.

Authors:  Zheng Chen; Bili Wang; Shanshan Mao; Qing Ye
Journal:  Int J Biol Sci       Date:  2021-03-10       Impact factor: 6.580

Review 7.  Cellular Immune Response to COVID-19 and Potential Immune Modulators.

Authors:  Xi Zhou; Qing Ye
Journal:  Front Immunol       Date:  2021-04-30       Impact factor: 7.561

Review 8.  The global epidemic of SARS-CoV-2 variants and their mutational immune escape.

Authors:  Dandan Tian; YanHong Sun; JianMing Zhou; Qing Ye
Journal:  J Med Virol       Date:  2021-10-13       Impact factor: 20.693

Review 9.  The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape.

Authors:  Dandan Tian; Yanhong Sun; Jianming Zhou; Qing Ye
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

Review 10.  miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19.

Authors:  Brandon Bautista-Becerril; Guillermo Pérez-Dimas; Paola C Sommerhalder-Nava; Alejandro Hanono; Julio A Martínez-Cisneros; Bárbara Zarate-Maldonado; Evangelina Muñoz-Soria; Arnoldo Aquino-Gálvez; Manuel Castillejos-López; Armida Juárez-Cisneros; Jose S Lopez-Gonzalez; Angel Camarena
Journal:  Viruses       Date:  2021-12-27       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.